FR2999914A1 - Use of 6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-hexanoic acid or its salt in a cosmetic composition for e.g. preventing and/or treating skin changes associated with aging and/or photoaging and the loss of firmness of the skin - Google Patents

Abstract

Use of 6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-hexanoic acid (I) or its salt for preventing and/or treating skin changes associated with aging and/or photoaging, is claimed. Use of 6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-hexanoic acid of formula (I) or its salt for preventing and/or treating skin changes associated with aging and/or photoaging, is claimed. A : benzene ring, optionally substituted by one or more substituents consisting of 1-5C alkyl; and m : 1-12. [Image] ACTIVITY : Dermatological. MECHANISM OF ACTION : Collagen, type III, alpha 1 (COL3A1) modulator.

Description

The invention relates to the use of derivatives of imidocarboxylic acid, preferably 6- (1,3-dicarboxylic acid). dioxo-1,3-dihydro-isoindo1-2y1) -hexanoic acid, as agents for preventing and / or treating age-related and / or photo-aging-related skin changes.

During the aging process, there are various signs on the skin very characteristic of this aging, resulting in particular in a modification of the structure and cutaneous functions. This aging is physiological in nature but it can also be photoinduced, which is due to repeated or exceptional exposure of the skin to sunlight, especially ultraviolet.

The main clinical signs of skin aging include the appearance of fine lines and deep wrinkles, which increases with age. In particular, there is disorganization of the "grain" of the skin, that is to say that the micro-relief is less regular and has an anisotropic character. Another clinical sign of aging is the dry, rough appearance of the skin, which is essentially due to greater desquamation; these dander, by diffracting the light rays, also participate in the gray appearance of the complexion. Finally, there is a loss of firmness and tonicity of the skin resulting in a lack of flexibility which, as for wrinkles and fine lines, is at least partly explained by a dermal and epidermal atrophy and a flattening of the skin. dermoepidermal formation; the skin is less thick and flaccid, and the thickness of the epidermis decreases. We thus note that the clinical signs of cutaneous aging result essentially from a dysfunction of the main biological mechanisms intervening on the level of the skin.

Photo-aging is the result, at the level of the dermis, of the degradation of the collagen fibers resulting in particular in clinical alterations such as thick wrinkles and the formation of a soft and tanned skin. The aging of the skin is accelerated by chronic exposure to ultraviolet. There is therefore a need for new agents, capable of preventing and / or treating age-related and / or photo-aging-related skin changes.

The object of the present invention is therefore to provide a compound intended to prevent and / or treat age-related skin and / or photo-aging alterations for a cosmetic composition. Surprisingly, the inventors have shown that the compounds of formula (I) below, such as 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid, have intrinsic to the skin and especially to the dermis. Thus, the subject of the present invention is the use of a compound of formula (I): ## STR2 ## in which: A represents a benzene ring, optionally substituted with one or more, preferably up to 4, even more preferably by 1 or 2 substituents selected from among the (C1-C5) alkyl groups, m is an integer chosen from 1 to 12, for example from 1 to 10 or for example from 1 to 6, or a salt thereof, as an agent for preventing and / or treating skin disorders related to age and / or photo-aging. According to one embodiment of the invention, in formula (I), A is an unsubstituted benzene. In another embodiment, A is unsubstituted benzene and m is 1 to 5.

Among the (C1-C5) alkyl groups, mention may be made of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl and pentyl. The salts of the compounds of formula (I) that may be used are in particular chosen from alkali metal salts such as sodium and potassium salts; alkaline earth metal salts such as, for example, calcium, magnesium and strontium salts; for example, salts of zinc, aluminum, manganese and copper; ammonium salts of formula NH4; quaternary ammonium salts, organic amine salts such as, for example, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, 2-hydroxyethylamine, bis (2-hydroxyethyl) amine and tri (2-hydroxyethyl) amine salts; and arginine and lysine salts. Preferably, the salts are sodium, potassium, magnesium, strontium, copper, manganese and zinc salts. Preferably, the sodium salts are used.

Preferably, the compound of formula (I) is 6- (1,3-dioxo-1,3-dihydroisoindol-2-yl) -hexanoic acid. 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid, CAS No. 4443-26-9, also known as PAC, phthalimido hexanoic acid, phthalimido caproic acid or c-phthalimido hexanoic acid is an acid of structural formula: This compound is described in patent application WO2012 / 076345. "Cosmetic composition" is understood to mean a substance or a preparation intended to be brought into contact with the various superficial parts of the human body, in particular the epidermis, the hair and capillary systems, the nails, the lips and the external genital organs, or with the teeth and oral mucous membranes, with a view, exclusively or mainly, to clean, perfume, modify the appearance, protect them, maintain them in good condition or correct body odor. A cosmetic composition is intended for non-therapeutic use. The cosmetic composition may be intended to be applied to the skin. By "skin" is meant the skin of the face and / or the body, the scalp and the semi-mucous membranes (lips). The use of the compounds of formula (I) as defined above, preferably 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid according to the invention may be intended to prevent and / or treat the loss of firmness of the skin and / or pores of the skin. The use of the compounds of formula (I) according to the invention may be intended to reduce the appearance and / or the visibility of the pores. In particular, the use according to the invention may be intended to prevent and / or treat the appearance of wrinkles and / or fine lines. By "prevention" or "prevention" is meant according to the invention the fact of reducing the risk of occurrence or slowing down the occurrence of a given phenomenon, namely, according to the present invention, age-related changes. (skin aging) or photo-aging. By "cosmetic treatment of wrinkles and / or fine lines" is meant according to the present invention the fading of wrinkles and / or fine lines, or to reduce the appearance of wrinkles and / or fine lines.

The use according to the invention is particularly intended to prevent and / or treat the lack of flexibility of the skin. These alterations of the skin can be as much the consequence of age-related changes as the consequence of daily or exceptional solar exposure. The cosmetic compositions comprising a compound of formula (I) as defined above, preferably 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid, as agent for preventing and / or treating age-related skin and / or photo-aging alterations further comprise a physiologically acceptable medium. A physiologically acceptable medium is a non-toxic medium that can be applied to human skin and has a pleasant appearance, odor and feel. Said compound of formula (I) as defined above is preferably used in a cosmetic composition in an amount ranging from 0.01% to 20% by weight relative to the total weight of the cosmetic composition. Preferably, the compound of formula (I), preferably 6- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -hexanoic acid, is present in an amount of 0.1% to 10% by weight relative to the total weight of the composition. The compound of formula (I) is more preferably present in an amount of from 0.1% to 5% by weight relative to the total weight of the composition. In the cosmetic composition according to the invention, the compound of formula (I) as defined above, preferably 6- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) hexanoic acid, can be combined with at least one other active agent chosen from tensors, dermal matrix stimulating agents, fibroblast stimulating agents or keratinocytes, dermorelaxation promoting agents, cellular energy and / or cutaneous microcirculation, agents modulating complexions and stains and desquamating agents. Tensing agents: "Tensing agents" means compounds that may have an apparent tensing effect, that is to say smooth the skin and reduce or even disappear, immediately, wrinkles and fine lines. Dermal matrix stimulating agents: Dermal matrix stimulating agents are agents which stimulate the macromolecules of the dermis or prevent their degradation.

Fibroblast and keratinocyte stimulating agents: By "fibroblast and keratinocyte stimulating agents" are meant agents which, via their stimulating action, will have a reinforcing effect on the barrier function of the skin, as well as on the state of the skin. the epidermis.

The cosmetic composition may further comprise, as an excipient, at least one hydrophilic or lipophilic gelling agent, a hydrophilic or lipophilic additive, an emulsifying agent, a filler, in particular for hiding the microrelief, a stabilizing agent, a preservative, an antiseptic agent, a perfume, an odor absorber, a silicone derivative, an oil, a wax, an anti-UVA or UVB filter, a solvent, a surfactant or a dyestuff. The amounts of these various excipients are those conventionally used in the cosmetics field, and for example vary from approximately 0.01% (3/0 to 10%) of the total weight of the composition, which excipients, depending on their nature, may to be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules As oils or waxes that may be used in the invention, mention may be made of mineral oils (liquid petroleum jelly), vegetable oils (liquid fraction of shea butter, sunflower oil, apricot oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes, also known as silicone derivatives (cyclomethicone, cyclopentasiloxane, cyclohexasiloxane) and fluorinated oils (perfluoropolyethers), beeswax, carnauba wax, paraffin wax or shea butter, to which may be added fatty alcohols (cetyl alcohol) and fatty acids (stearic acid) e) As emulsifiers that can be used in the invention, mention may be made, for example, of fatty acid esters of polyethylene glycol, esters of fatty acid and of polyol such as glycerol linoleate and glycerol oleate. glycerol linolenate, glycerol stearate and sorbitan tristearate, polysorbate 60 and the PEG-6 / PEG32 / glycol stearate mixture sold under the name Tefose 63 by Gattefosse. As solvents that can be used in the invention, mention may be made of water, lower alcohols, in particular ethanol, isopropanol, and tert-butanol. As hydrophilic gelling agents that may be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates, hydrophobic silica, ethylcellulose and polyethylene. The fillers can be mineral or organic of any shape, platelet, spherical or oblong, irrespective of the crystallographic form (for example sheet, cubic, hexagonal, orthorhombic, etc.). Mention may be made of talc, mica, silica, kaolin, polyamide (Nylon®) powders (Orgasol® from Atochem), poly-p-alanine and polyethylene, tetrafluoroethylene polymer powders (Teflonl, lauroyl-lysine, starch, boron nitride, polymeric hollow microspheres such as those of polyvinylidene chloride / acrylonitrile such as Expancel® (Nobel Industrie), copolymers of acrylic acid (Polytrap® from Dow) Corning) and silicone resin microbeads (Toshiba Tospearls®, for example), elastomeric polyorganosiloxane particles, precipitated calcium carbonate, magnesium carbonate and magnesium carbonate, hydroxyapatite, silica microspheres hollow (Silica Beads® from Maprecos), glass or ceramic microcapsules, metal soaps derived from organic carboxylic acids containing from 8 to 22 carbon atoms, preferably from 12 to 18 carbon atoms, for example zinc, magnesium or lithium stearate, zinc laurate and magnesium myristate. As fillers which can hide the microrelief, mention may be made, for example, of silica microparticles such as Sunspheres, silicone particles marketed under the reference NLK by Takemoto, particle powders such as Covabead, Flobeads, KSP 100, fibers and composite powders. Finally, as filters, mention may in particular be made of organic UV screening agents chosen from hydrophilic organic screening agents, lipophilic organic screening agents and mixtures thereof. According to a particular embodiment of the invention, one or more physical filters can be associated with it. For example, designated above under their CTFA name (Cosmetics, Toiletry and Fragrance Association become the Personal Care Products Council): - The derivatives of para-aminobenzoic acid (PABA): PABA, Ethyl PABA, Ethyl Dihydroxypropyl PABA, Ethylhexyl Dimethyl PABA, Glyceryl PABA, PEG-25 PABA; Salicylic derivatives: homosalate, ethylhexyl salicylate (or ethyl hexyl salicylate), dipropylene glycol salicylate, TEA salicylate; Derivatives of dibenzoylmethane: Butyl Methoxydibenzoylmethane and Isopropyl Dibenzoylmethane; Cinnamic derivatives: Ethylhexyl Methoxycinnamate (or Octyl Methoxycinnamate), Isopropyl Methoxycinnamate, Isoamyl Methoxycinnamate, Cinoxate, DEA Methoxycinnamate, Diisopropyl Methylcinnamate, Glyceryl Ethylhexanoate Dimethoxycinnamate; - Derivatives of [3, 3-diphenylacrylate: Octocrylene (α-cyano-p, [3-diphenylacrylate 2-ethylhexyl) and Etocrylene; Benzophenone derivatives: Benzophenone-1, Benzophenone-2, Benzophenone-3 or Oxybenzone, Benzophenone-4, Benzophenone-5, Benzophenone-6, Benzophenone-8, Benzophenone-9 and Benzophenone-12; Benzylidenecamphor derivatives: 3-Benzylidene camphor, 4-methylbenzylidene camphor, Benzylidene Camphor Sulfonic Acid, Camphor Benzalkonium Methosulfate, Terephthalylidene Dicamphor Sulfonic Acid and Polyacrylamidomethyl Benzylidene Camphor; Phenyl benzimidazole derivatives: Phenylbenzimidazole Sulfonic Acid and Benzimidazilate; - The triazine derivatives: Anisotriazine, Ethylhexyl triazone and Diethylhexyl Butamido Triazone; Phenyl benzotriazole derivatives: Drometrizole Trisiloxane; - Anthranilic derivatives: Menthyl anthranilate; Imidazoline derivatives: Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate; Benzalmalonate derivatives: Polyorganosiloxane with benzalmalonate functions; - And their mixtures.

The cosmetic composition may also comprise water in sufficient quantity to reach 100% of the total weight of the composition. According to one particular embodiment of the present invention, the cosmetic composition is intended for topical or oral administration.

For oral administration, the cosmetic composition according to the invention can be in any suitable form, in particular in the form of an oral solution, a tablet, a capsule, a capsule or even a food or nutritional supplement. According to this embodiment, the cosmetic composition comprises a compound of formula (I) as defined above such as 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid, and at least one cosmetically acceptable vehicle which is an excipient suitable for oral administration.

For a topical application to the skin, the composition may have the form in particular of aqueous or oily solutions or of dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a phase in the aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions of soft consistency of the cream or gel type aqueous or anhydrous, or microcapsules or microparticles, or vesicular dispersions ionic type and / or nonionic or foams. These compositions are prepared according to the usual methods. These cosmetic compositions may for example constitute creams for cleaning, protecting, treating or caring for the face, for the hands, for the feet, for large anatomical folds or for the body (for example, day creams, creams for night creams, make-up creams, foundation creams, sunscreen creams), fluid foundations, make-up removing milks, body care or protection milks, sunscreen lotions, lotions, gels or mousses for skin care, such as cleaning lotions, sunscreen lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions and depilatory creams . The compositions may also consist of solid preparations constituting soaps or cleaning bars.

The compositions may also be packaged in the form of an aerosol composition also comprising a propellant under pressure. A composition may also be a composition for the care of the scalp, and especially a shampoo, a styling lotion, a treatment lotion, a cream or a styling gel, a composition of dyes, optionally in the form of coloring shampoos, lotions Restructuring for the hair, a composition of permanent (including a composition for the first time of a permanent), a lotion or a gel fall, a shampoo antiparasitic, anti-dandruff etc. The composition may be formulated as an emulsion, cream, ointment, balm, milk, lotion, gel, mousse or solution.

The composition may in particular be chosen from moisturizing compositions, compositions for the prevention and / or treatment of oily skin, anti-aging compositions, shaving products, after-sun products, soothing creams or products. specifically for the lips, eyes or legs. In particular, the composition may be chosen from sunscreen or after-sun compositions, night creams, beauty serums and anti-aging compositions.

It can impregnate various supports, fabric or non-woven, such as clothing. Preferably, the composition may be chosen from masks applied to the skin, with or without rinsing, care applied to the skin or the scalp, with or without rinsing, or pre-impregnated textiles.

The invention also relates to a cosmetic process for the non-therapeutic care of the skin, intended to prevent and / or treat age-related skin changes and / or photoaging, characterized in that it comprises less a step of applying to the skin, a cosmetic composition according to the present invention. More particularly, the cosmetic process according to the invention is intended to prevent and / or treat the loss of firmness of the skin and / or pores and / or the appearance of wrinkles and / or fine lines and / or the lack of flexibility. skin. The properties of the compounds of formula (I) as defined above, and more particularly of 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid (PAC), have highlighted by the examples and figures below. By way of example, a composition for carrying out the present invention is a composition as described in Examples 2 to 4. The compounds are, as the case may be, cited in chemical names or CTFA names (International Cosmetic Ingredient 20 Dictionary and Handbook). These compositions can be manufactured conventionally in the field under consideration. FIGURES Figures 1 and 2 illustrate the results of the study described in the Example below. They respectively represent the effect of 6- (1,3-dioxo-1,3-dihydroisoindol-2-yl) -hexanoic acid (PAC) on the expression of the COL3A1 and DON genes. EXAMPLES In the examples, the concentration given corresponds to the percentage by weight relative to the total weight of the compositions.

Example 1 Material and Protocol 1- In Vitro Model: The model used is a 3-dimensional reconstructed skin model called Henkel's Phenion® Full thickness skin model. The diameter is 1.3 cm. The protocol is done in duplicate. After receiving the skin model, the skin is kept for 2 days following the instructions in a culture medium. After 2 days, 4 symmetrical injuries performed mechanically and reproducibly are applied to each skin. The skin is then treated on the surface with 50 μl of 0.8% PAC in water (T 2 O). The skin is replaced in a thermostatically controlled incubator (37 ° C, 5% 002, 90% RH). The PAC is reapplied at 6 o'clock. The tests are performed at 6, 24 and 96 hours. 2- Transcriptomic study The analysis is based on a transcriptomic approach (gRT-PCR). Each sample is suspended in a buffer and mRNAs are extracted at 6, 24 and 96 hours. For the extraction process, the method is fast and phenol-free and allows to isolate the RNA through a filter. It is based on the ability of glass fibers to bind with nucleic acids in a concentrated solution of chaotropic salts represented by guanidinium salts which lyse cells and inactivate endogenous RNases. RNAs bind to the level of the filter disk. The filter is washed and the RNAs are eluted using a solution of low ionic strength. The concentration of each RNA is then evaluated spectrophotometrically at 268/280 nm. RNA is detected by a cDNA reverse transcription kit that uses random primers to initiate cDNA synthesis. The use of random primers makes it possible to ensure that the synthesis of the first strands is effected efficiently with all the RNAs present.

RNA is converted to cDNA which is then used for real-time PCR. The instrument "Applied Biosystems 7500 real time PCR" is used to perform a chemical PCR, with technology "Taqman assay". The accumulation of PCR products is detected by following the fluorescence growth.

The expression of the following genes has been studied on skins treated with PAC versus untreated skin: COL3A1; and Deconne or DON. The COL3A1 gene is a gene encoding fibrillar collagen found in association with collagen 1. It participates in the extensibility properties of the skin. DON is a gene of the proteoglycan family. This gene intervenes in the regulation of the dermal matrix and restores the integrity of this matrix function in particular in the organization of collagen fibrils. Results The PAC, under these conditions, modulates the expression of the COL3A1 gene and the DON gene from 6 hours of application and significantly with respect to the control, as indicated in Table 1 below. Table 1 Dermal remodeling activity 6H 24H 96H COL3A1 + + DCN + + Figure 1 shows the effect of PAC on the expression of the Deconnee gene at 6 o'clock and demonstrates a significant increase of this expression in areas where 25 the PAC was applied against the witness. Similarly, Figure 2 depicts the effect of PAC on the expression of the COL3A1 gene and the results show a significant increase in gene expression at 6 hours for areas where PAC has been applied versus to the witness. This increase is still significant at 96 hours. Conclusion The observed inhibition of COL3A1 and DON gene expression demonstrates modulation and direct action of PAC on dermal remodeling.

The decoon has been described as being diminished in the skin subjected to UV exposures (J Korean Med. Sci.

2011 Mar; 26 (3): 417-24.Epub 2011 Feb 25: transcriptional regulation of proteoglycans and glycosaminglycan chain-synthesizing glycosyltransferases by UV irradiation in cultured human dermal fibroblasts), we can conclude that there is interest in the PAC for the treatment of photo-treated skin. subject to UV exposure. It is also known from the literature that mature skin experiences a decrease in collagen. For example, vitamin C is a treatment for mature skin used among the references. A long-term study has shown that the effect of vitamin C passes through an increase in the expression of the genes of Collagens 1 and 3 and Deconne (J Invest Dermatol.

2011 Jun; 116 (6): 853-9: topically applied vitamin C enhances the mRNA level of collagen 1 and 3, their processing enzymes and tissue inhibitor matrix metalloproteinase 1 in the human dermis). The PAC having an equivalent profile can therefore be used for the anti-aging treatment. EXAMPLE 2 Anti-Aging Cream Preparation Process: Prepare the emulsion by weighing the oily phase on one side and add the aqueous phase with vigorous stirring to a turbine, and add finally the powders, the perfume and the alcohol. Components Concentration Fragrance 0.20 Tocopherol 0.50 Disodium EDTA 0.10 Nylon 12 1.80 Acrylate Copolymers (Expancel 551) 0.264 Glycerin 5.00 lsohexadecane 3.00 dicaprylyl carbonate 2.00 PEG / PPG - 18/18 dimeth icone (DC5225 C) 1.80 Polysorbate 20 0.50 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid 2.50 Denatured alcohol 1.50 Sodium hyaluronate 0.02 lsobutane ( Expancel 551) 0.036 Preservative 0.80 Water QSP 100 Example 3: Night cream Preparation method: Heat the fatty phase at 80 ° C., Swell the gelling agent in water heated to 75 ° C. with gentle stirring, Disperse water in the aqueous phase with vigorous stirring, cool with gentle stirring, then add the final ingredients, fragrances and preservatives. Components Concentration Glyceryl Stearate SE 3.00 Myristic Alcohol 0.10 Stearyl Alcohol 0.10 Sodium Hydroxide 0.05 Myristyl Myristate 2.00 Cetyl Alcohol 3.80 Sodium Copolymers Styrene / MA 0.50 PEG-40 Stearate (Myrj 52P) 2.00 Myristic acid 0.036 Palmitic acid 0.528 Stearic acid 0.636 "Prunus armeniaca kernel" oil 2.00 Petrolatum 4.00 6- (1,3-dioxo-1,3-dihydro-isoindo-2-yl) -hexanoic acid 1 , 00 Denatured alcohol 2.00 Preservative 0.80 Perfume 0.30 Water QSP 100 Example 4: Beauty serum Production method: Heat the fatty phase at 80 ° C., Inflate the gelling agent in the water heated to 75 ° C. C with gentle stirring, then disperse the water in the aqueous phase with vigorous stirring, and cool with gentle stirring and finally add the active ingredients, fragrances and preservatives. Components Concentration Hydroxyethylcellulose 0.20 Xanthan gum 0.25 Potassium cetyl phosphate 0.10 EDTA disodium 0.05 Dipropylene glycol 7.00 Glycerin 5.00 Silica 0.80 Glyceryl stearate (and) stearate PEG-100 1, 42 Cetyl alcohol 0.80 Stearic acid 1.00 Dimethicone 5.00 Neopentyl glycol dicaprate 2.00 Tocopheryl acetate 1.00 Carbomer 0.30 Potassium hydroxide 0.40 6- (1,3-dioxo-1 acid) 3-dihydro-isoindo1-2y1) -hexanoic 1.00 Denatured alcohol 2.00 Perfume 0.10 Water QSP 100

Claims (13)

REVENDICATIONS1. Use of a compound of formula (I): (I) in which: - A represents a benzene ring, optionally substituted with one or more substituents selected from the groups (C1-C5) alkyl, - m is an integer selected from 1 to 12, or one of its salts, as an agent for preventing and / or treating skin damage related to age and / or photo-aging. 2. Use according to claim 1 for preventing and / or treating loss of firmness of the skin. 3. Use according to claim 1 for reducing the appearance and / or visibility of pores. 20 4. Use according to claim 1 or 2, for preventing and / or treating the appearance of wrinkles and / or fine lines. 5. Use according to claim 1 or 2, for preventing and / or treating the lack of suppleness of the skin. 25 6. Use according to any one of the preceding claims wherein the compound of formula (I) is 6- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) hexanoic acid. 30 7. Use according to any one of claims 1 to 6, wherein the compound of formula (I) is used in a cosmetic composition in an amount ranging from 0.01% to 20% by weight relative to the total weight of the cosmetic composition. 8. Use according to claim 7, wherein the cosmetic composition comprises from 0.1% to 10% by weight of the compound of formula (I) relative to the total weight of the cosmetic composition. 9. Use according to any one of claims 1 to 8, wherein the compound of formula (I) is associated with at least one other active agent selected from tensors, dermal matrix stimulating agents, fibroblast stimulating agents or keratinocytes, agents promoting dermorelaxation, cellular energy, and / or cutaneous microcirculation, complexing agents for complexions and stains and desquamating agents. 10. Use according to any one of claims 1 to 9, wherein the cosmetic composition further comprises as an excipient at least one hydrophilic or lipophilic gelling agent, a hydrophilic or lipophilic additive, an emulsifying agent, a stabilizing agent, a preservative, an antiseptic agent, a perfume, an odor absorber, a silicone derivative, an oil, a wax, an anti-UVA or UVB filter, a solvent, a charge for hiding the microrelief or a coloring matter. 11. Use according to any one of claims 1 to 10, wherein the cosmetic composition is intended for topical or oral administration. 12. Use according to any one of claims 1 to 11, wherein the cosmetic composition is formulated in the form of emulsion, cream, ointment, balm, milk, lotion, gel, mousse or solution. . 13. Use according to any one of claims 1 to 12, wherein the cosmetic composition is selected from sunscreen compositions, after-sun compositions or anti-aging compositions.